Up to 100,000 newborn babies in England are set to undergo screening for dozens of genetic conditions in a groundbreaking research project within the NHS. Named the Generation Study, the initiative led by Genomics England and NHS England will involve offering whole genome sequencing using blood samples from newborns, typically taken from the umbilical cord shortly after birth.
This study aims to identify over 200 rare conditions, such as Metachromatic leukodystrophy (MLD), which results in a gradual loss of physical and mental abilities. Currently, more than 500 blood samples have been collected from newborns at 13 NHS hospitals, with plans to expand to around 40 hospitals in the future. Detecting these rare genetic conditions earlier could enable hundreds of children to receive timely diagnosis and treatment, potentially slowing down disease progression or increasing their life expectancy.
Whole genome sequencing gives a comprehensive view of an individual’s genetic code to pinpoint changes related to specific health conditions. The Generation Study targets healthy-looking babies who may not show symptoms until later in life. Pregnant women and their partners are being informed about the research during routine checks and invited to participate. If they agree, a blood sample is collected at birth and sent for sequencing, with results shared within 28 days if a condition is suspected.
Health and Social Care Secretary, Wes Streeting, highlighted the importance of predictive and personalised healthcare for the future, aiming to offer families prompt support and treatment. NHS chief executive Amanda Pritchard emphasised the potential life-changing impact of diagnosing rare conditions in newborns early, providing families with the opportunity for timely interventions and care planning.
Although the routine NHS blood spot screening for nine rare health conditions in newborns remains unchanged, the Generation Study acts as an additional test to enhance early detection. The study launch marks a crucial moment, helping reduce the time children with rare conditions spend without a diagnosis. One parent, Lucy White, shared her experience of delayed diagnosis for her son’s terminal early juvenile MLD, stressing the urgency of early detection for accessing life-altering treatments.
Research aims to uncover more about the genetic links to health, potentially leading to innovative treatments, and storing genetic data from birth could aid individuals diagnosed with illnesses later in life. The study hopes to provide invaluable insights and support for affected families while advancing medical understanding of rare genetic conditions.